Blue Fin Capital Inc. Increases Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Blue Fin Capital Inc. raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 52.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,346 shares of the medical equipment provider’s stock after acquiring an additional 462 shares during the quarter. Blue Fin Capital Inc.’s holdings in Intuitive Surgical were worth $599,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Cadinha & Co. LLC boosted its position in shares of Intuitive Surgical by 1.0% in the second quarter. Cadinha & Co. LLC now owns 57,841 shares of the medical equipment provider’s stock worth $25,731,000 after acquiring an additional 594 shares during the last quarter. Mirova US LLC raised its stake in shares of Intuitive Surgical by 2.1% during the second quarter. Mirova US LLC now owns 377,745 shares of the medical equipment provider’s stock valued at $168,040,000 after purchasing an additional 7,933 shares during the period. Canal Capital Management LLC raised its stake in shares of Intuitive Surgical by 0.9% during the second quarter. Canal Capital Management LLC now owns 8,620 shares of the medical equipment provider’s stock valued at $3,835,000 after purchasing an additional 73 shares during the period. Americana Partners LLC increased its stake in shares of Intuitive Surgical by 1.1% in the second quarter. Americana Partners LLC now owns 3,313 shares of the medical equipment provider’s stock worth $1,474,000 after buying an additional 37 shares during the last quarter. Finally, Bryn Mawr Capital Management LLC increased its stake in shares of Intuitive Surgical by 3.8% in the second quarter. Bryn Mawr Capital Management LLC now owns 1,428 shares of the medical equipment provider’s stock worth $635,000 after buying an additional 52 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on ISRG. Truist Financial upped their target price on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Evercore ISI reduced their price objective on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. BTIG Research raised their target price on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday. Citigroup boosted their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, The Goldman Sachs Group started coverage on Intuitive Surgical in a report on Thursday, May 30th. They set a “buy” rating and a $500.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $492.63 on Friday. The firm has a market cap of $175.06 billion, a price-to-earnings ratio of 88.92, a P/E/G ratio of 5.43 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $493.97. The stock has a 50-day simple moving average of $454.69 and a 200-day simple moving average of $414.46.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.18 EPS. As a group, equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Robert Desantis sold 188 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $411.00, for a total value of $575,400.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,552 shares of company stock worth $26,281,657. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.